Combination preparation containing heterocyclidene acetamide derivative

MYPI2025001923A0Undetermined Publication Date: 2024-03-29MOCHIDA PHARM CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001923
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-09-29
Filing Date
2023-09-28
Publication Date
2024-03-29

AI Technical Summary

Technical Problem

Current dry eye treatments, such as eye drops, often require frequent administration due to poor redispersibility of suspended particles, leading to inconsistent delivery of active ingredients and reduced pharmacological effectiveness, which can deter patient adherence and convenience.

Method used

An aqueous suspension formulation containing (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, combined with diquafosol, cyclosporin, hyaluronic acid, loteprednol etabonate, bromfenac, or fluorometholone, and a nonionic surfactant like tyloxapol, polysorbate 80, or polyoxyethylene hydrogenated castor oil, to enhance redispersibility and stability, allowing for uniform distribution of active ingredients.

Benefits of technology

The formulation improves redispersibility, ensuring that suspended particles are uniformly dispersed after fewer inversions, stabilizing the administration of active ingredients and enhancing pharmacological effects, thus improving patient adherence and convenience by reducing the frequency of administration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PI2025001923_DRAWING_001
    Figure PI2025001923_DRAWING_001
Patent Text Reader

Abstract

The present disclosure provides a suspension-type ophthalmic solution having excellent re-dispersibility. More specifically, the present disclosure provides a water-based suspension preparation containing a first component and a second component, in which the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component comprises at least one component selected from the group consisting of diquafosol, ciclosporin, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone and pharmaceutically acceptable salts or solvates thereof. Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Combination drugs containing heterocyclideneacetamide derivatives

[0001] The present disclosure relates to the fields of medicine, healthcare, biology, biotechnology, etc. In particular, the present disclosure relates to a technology for improving the redispersibility of a suspension containing a heterocyclideneacetamide derivative, and a formulation technology based thereon.

[0002] The number of dry eye patients in Japan is estimated to be at least 8 million, and the number is estimated to be approximately 22 million, including potential patients who use over-the-counter eye drops without visiting a doctor. It is estimated that there are over 1 billion dry eye patients worldwide. In modern society, the use of television, computers, mobile devices, and other devices increases the frequency of staring at screens, reducing the number of blinks. Furthermore, the use of air conditioners and other devices dries the air, resulting in increased tear evaporation and leading to dry eye. Furthermore, refractive surgery and the use of contact lenses can result in dry eye. Symptoms associated with dry eye include ocular discomfort, dryness, burning, and irritation of the ocular surface.

[0003] When dry eye occurs, the above symptoms appear as subjective symptoms, and treatment requires regular eye drops over a long period of time. Therefore, many of the currently commercially available dry eye treatments are of the frequent administration type. For example, Diquas (registered trademark) eye drops usually need to be instilled six times a day, Hyalein (registered trademark) eye drops usually need to be instilled five to six times a day, and Mucosta (registered trademark) eye drops usually need to be instilled four times a day.

[0004] A composition containing (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, or use thereof for treating dry eye has been disclosed (Patent Document 1).

[0005] Patent Document 1: International Publication No. 2021 / 066144 Pamphlet

[0006] The present disclosure provides an aqueous suspension having excellent redispersibility, which comprises, as a first component, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, which is a heterocyclideneacetamide derivative, or a pharmaceutically acceptable salt or solvate thereof, and, as a second component, at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

[0007] Accordingly, the present disclosure provides the following: (Item 1) An aqueous suspension comprising a first component and a second component, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof. (Item 2) The aqueous suspension according to the above items, further comprising a nonionic surfactant. (Item 3) The aqueous suspension according to any one of the above items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. (Item 4) The aqueous suspension according to any one of the above items, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60. (Item 5) The aqueous suspension according to any one of the above items, wherein the nonionic surfactant is tyloxapol. (Item 6) The aqueous suspension according to any one of the above items, wherein the concentration of the nonionic surfactant in the aqueous suspension is about 0.0001 w / v% to about 1 w / v%. (Item 7) The aqueous suspension according to any one of the above items, wherein the concentration of the first component in the aqueous suspension is about 0.01 w / v% to about 5 w / v%. (Item 8) The aqueous suspension according to any one of the above items, wherein the concentration of the first component in the aqueous suspension is about 0.3 w / v% to about 1 w / v%. (Item 9) The aqueous suspension according to any one of the preceding items, wherein the concentration of the second component in the aqueous suspension is about 0.005 w / v % to about 10 w / v %.(Item 10) The concentration of the diquafosol or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.3 w / v% to about 10 w / v%, the concentration of the cyclosporine or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.005 w / v% to about 0.5 w / v%, the concentration of the hyaluronic acid or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v% to about 1 w / v%, the concentration of the loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.025 w / v% to about 2.5 w / v%, the concentration of the bromfenac or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v% to about 1 w / v%, Item 11. The aqueous suspension according to any one of the preceding items, wherein the concentration of fluorometholone or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v % to about 1 w / v %. (Item 12) The aqueous suspension according to any one of the preceding items, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof. (Item 13) The aqueous suspension according to any one of the preceding items, further comprising boric acid. (Item 14) The aqueous suspension according to any one of the preceding items, wherein the pH of the aqueous suspension is about 4 to about 8. (Item 14) The aqueous suspension according to any one of the preceding items, wherein the redispersibility of the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is improved. (Item 15) The aqueous suspension according to any one of the preceding items, wherein the improved redispersibility is such that the suspended particles redisperse after about 30 or fewer inversions when evaluated by inversion.(Item A1) An aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. (Item A2) An aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.(Item A3) An aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60, and the concentration of the first component in the aqueous suspension is about 0.01 w / v % to about 5 w / v %. The aqueous suspension has a concentration of the second component in the aqueous suspension of about 0.005 w / v % to about 10 w / v %, and a concentration of the nonionic surfactant in the aqueous suspension of about 0.0001 w / v % to about 1 w / v %.(Item A4) An aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60, and the concentration of the first component in the aqueous suspension is about 0.01 w / v % to about 5 w / v %. the concentration of the diquafosol or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.3 w / v% to about 10 w / v%, the concentration of the cyclosporine or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.005 w / v% to about 0.5 w / v%, the concentration of the hyaluronic acid or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v% to about 1 w / v%, the concentration of the loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.025 w / v% to about 2.5 w / v%, the concentration of the bromfenac or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v% to about 1 w / v%, The aqueous suspension contains fluorometholone or a pharmaceutically acceptable salt or solvate thereof at a concentration of about 0.01 w / v % to about 1 w / v %. The aqueous suspension contains the nonionic surfactant at a concentration of about 0.0001 w / v % to about 1 w / v %.(Item A5) An aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60, and the concentration of the first component in the aqueous suspension is about 0.3 w / v % to about 1 w / v %. the aqueous suspension having a concentration of the diquafosol or a pharmaceutically acceptable salt or solvate thereof of about 3 w / v %, the cyclosporine or a pharmaceutically acceptable salt or solvate thereof of about 0.05 w / v %, the hyaluronic acid or a pharmaceutically acceptable salt or solvate thereof of about 0.1 w / v %, the loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof of about 0.25 w / v %, and the nonionic surfactant of about 0.01 w / v % to about 0.05 w / v %.(Item A6) An aqueous suspension comprising a first component, a second component, a nonionic surfactant, and boric acid, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60, the concentration of the first component in the aqueous suspension is about 0.3 w / v %. the concentration of the diquafosol or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 3 w / v%, the concentration of the cyclosporine or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.05 w / v%, the concentration of the hyaluronic acid or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.1 w / v%, the concentration of the loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.25 w / v%, the concentration of the bromfenac or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.1 w / v%, the concentration of the fluorometholone or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.1 w / v%, The aqueous suspension has a concentration of the nonionic surfactant in the aqueous suspension of about 0.01 w / v % to about 0.05 w / v %, a pH of about 4 to about 8, and when the redispersibility of the aqueous suspension is evaluated by inversion, the suspended particles are redispersed after about 30 or fewer inversions.(Item B1) A method for producing an aqueous suspension, comprising the step of mixing a first component, a second component, and a nonionic surfactant to prepare an aqueous suspension, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil. (Item C1) A method for improving the redispersibility of an aqueous suspension, comprising the step of preparing an aqueous suspension by mixing a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.

[0008] According to the present disclosure, an aqueous suspension having excellent redispersibility can be provided.

[0009] By providing the above-mentioned features, the present disclosure can suppress the phenomenon of non-uniform dispersion of suspended particles, enable stable administration of the required amount of active ingredient, and realize stable and sufficient exertion of pharmacological effects, thereby contributing to improved patient adherence and convenience.

[0010] FIG. 1 shows the transmittance at each wavelength of the body of the bottle of each container used in the examples.

[0011] The present disclosure will be described below. Throughout this specification, singular expressions should be understood to include the plural concept unless otherwise specified. Therefore, singular articles (e.g., "a," "an," "the," etc. in English) should be understood to include the plural concept unless otherwise specified. Furthermore, it should be understood that terms used in this specification are used in the sense commonly used in the relevant field unless otherwise specified. Therefore, unless otherwise defined, all technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will prevail.

[0012] (Definitions) In this specification, unless otherwise specified, the term "about" means ±10% of the following numerical value.

[0013] In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "or" and "alternative." In this specification, when it is specified that "within" "a range of two values," the range includes the two values ​​themselves.

[0014] As used herein, the term "aqueous suspension" is used in the same sense as commonly used in this field and refers to a liquid formulation containing at least a portion of water, in which the components to be mixed are suspended, and in which solid particles are present in the liquid. The first component, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, has extremely low solubility in water. Therefore, in the aqueous suspension formulation of the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, forms suspended particles, although some of the particles remain dissolved. In addition to the first component, the second component may also form suspended particles.

[0015] As used herein, "pharmaceutically acceptable salts" refers to relatively non-toxic, inorganic or organic acid addition salts, or inorganic or organic base addition salts of compounds of the present disclosure.

[0016] As used herein, the term "solvate" refers to a compound of the present disclosure or a pharmaceutically acceptable salt thereof interacting with any solvent to form a group, including, for example, solvates with organic solvents (e.g., solvates with alcohols (ethanol, etc.)), hydrates, etc. When a hydrate is formed, it may be coordinated with any number of water molecules. Examples of hydrates include monohydrates, dihydrates, etc.

[0017] As used herein, "redispersibility" refers to the ease with which particles (in the case of a suspension, also referred to as "suspended particles") that have settled in the solvent of a liquid containing the particles can be uniformly redispersed throughout the liquid after the liquid has been stored for a certain period of time. As used herein, "redispersibility" is evaluated by a test involving shaking or inversion.

[0018] As used herein, "shaking operation" refers to the action of holding a container filled with an "aqueous suspension" and shaking it up and down in the hand. The "shaking operation" involves shaking the container up and down in a 10-15 cm range, then shaking it up and back down until it returns to the original position, counting as one shaking operation, and shaking five times at a speed of 1.1 seconds per set. The redispersibility test using the "shaking operation" is performed on 3-6 samples per formulation, and the average number of sets required for redispersion for each sample is calculated, and this average number is used as the number of shaking operations.

[0019] As used herein, "inversion" refers to the action of holding a container filled with an "aqueous suspension" and turning it upside down in one hand. The redispersibility test using "inversion" is conducted on 3 to 6 specimens per formulation, and one inversion is defined as the operation of inverting the container 180° upside down at a rate of 1 second, then inverting it again 180° to return it to the upright position.

[0020] In this specification, "improved redispersibility" means that particles that have settled in a liquid containing particles, such as a suspension, become easier to disperse again. In a comparison of any formulation, if the number of "shaking operations" or "inversion operations" described above is reduced, it can be said that redispersibility has been improved.

[0021] As used herein, the term "average particle size of suspended particles" refers to the median particle size (D) of particles of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof. 50 ) and is a value measured using a laser diffraction particle size distribution analyzer.

[0022] In this specification, the term "nonionic surfactant" is also referred to as a nonionic surfactant, and refers to a surfactant in which the hydrophilic group portion is nonionic. Whether a surfactant is nonionic or not can be easily determined by a person skilled in the art, and can be determined by confirming that a surfactant does not ionize (does not exhibit ionicity) when dissolved in water. Examples of nonionic surfactants include tyloxapol, polyoxyl stearates (polyethylene glycol monostearate, polyethylene glycol 40 monostearate (MYS-40), polyethylene glycol 400 monostearate, etc.), polyoxyethylene sorbitan fatty acid esters (polyoxyethylene sorbitan monooleate (polysorbate 80), polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, etc.), and polyoxyethylene hydrogenated castor oils (polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60 (HCO-60), etc.).

[0023] (Preferred Embodiments) Preferred embodiments of the present disclosure will be described below. The embodiments provided below are provided for a better understanding of the present disclosure, and the scope of the present disclosure should not be limited to the following description. Therefore, it is clear that those skilled in the art can make appropriate modifications within the scope of the present disclosure in light of the description herein. In addition, the following embodiments of the present disclosure can be used alone or in combination.

[0024] (Aqueous Suspension) The present disclosure may provide an aqueous suspension comprising a first component and a second component, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of other active ingredients, and pharmaceutically acceptable salts or solvates thereof.

[0025] The present disclosure may provide an aqueous suspension comprising a first component and a second component, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

[0026] The present disclosure may provide an aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.

[0027] The present disclosure may provide an aqueous suspension comprising a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0028] The present disclosure may provide an aqueous suspension comprising a first component, a second component, a nonionic surfactant, and boric acid, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof; the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof; and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0029] In another aspect of the present disclosure, there is provided an aqueous suspension comprising a first component and a second component, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of rebamipide, olodaterol, delcocitinib, and a pharmaceutically acceptable salt or solvate thereof; or an aqueous suspension comprising the first component, the second component, a nonionic surfactant, and boric acid, wherein the first component is (E )-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of rebamipide, olodaterol, delcocitinib, and a pharmaceutically acceptable salt or solvate thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0030] In one aspect of the present disclosure, there can be provided a method for producing an aqueous suspension, the method comprising the step of mixing a first component and a second component to prepare an aqueous suspension, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

[0031] In still another aspect, there can be provided a method for producing an aqueous suspension, the method comprising the step of mixing a first component, a second component, and a nonionic surfactant to prepare an aqueous suspension, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.

[0032] In still another aspect, there can be provided a method for producing an aqueous suspension, the method comprising the step of mixing a first component, a second component, and a nonionic surfactant to prepare an aqueous suspension, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0033] In still another aspect, there can be provided a method for producing an aqueous suspension, the method comprising the step of mixing a first component, a second component, a nonionic surfactant, and boric acid to prepare an aqueous suspension, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0034] In another aspect of the present disclosure, there can be provided a method for improving the redispersibility of an aqueous suspension, the method comprising: mixing a first component and a second component to prepare an aqueous suspension, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

[0035] In still another aspect, there can be provided a method for improving the redispersibility of an aqueous suspension, the method comprising the step of preparing an aqueous suspension by mixing a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate, polyethylene glycol monostearate, and polyoxyethylene hydrogenated castor oil.

[0036] In still another aspect, there can be provided a method for improving the redispersibility of an aqueous suspension, the method comprising the step of preparing an aqueous suspension by mixing a first component, a second component, and a nonionic surfactant, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0037] In still another aspect, there can be provided a method for improving the redispersibility of an aqueous suspension, the method comprising the step of preparing an aqueous suspension by mixing a first component, a second component, a nonionic surfactant, and boric acid, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and pharmaceutically acceptable salts or solvates thereof, and the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

[0038] In the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide includes the R-form (CAS No. 920332-28-1), the S-form (CAS No. 920332-29-2), or the racemic form (CAS No. 920332-27-0), and more preferably the R-form ((E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide (also referred to as compound (1) in the present disclosure). Compound (1) that can be used in the present disclosure may be provided in any form; for example, it may be sterilized compound (1) or may be non-sterilized compound (1). Sterilization methods include dry heat sterilization, high-pressure steam sterilization, filtration sterilization, electron beam sterilization, gamma rays, ethylene oxide gas sterilization, and hydrogen peroxide gas sterilization, with dry heat sterilization being preferred. The treatment temperature for dry heat sterilization is not particularly limited, and is typically about 100 to about 175°C, preferably about 100 to about 170°C, and more preferably about 150 to about 170°C.

[0039] In the present disclosure, diquafosol refers to the active ingredient in the form of its salt (IUPAC: Tetrasodium P 1 ,P 4 Diquafosol is a compound formulated in Diquafosol ophthalmic solution as 5'-bis(5'-uridul)tetraphosphate / CAS. No. 211427-08-6. Diquafosol or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0040] In the present disclosure, cyclosporine refers to the compound (IUPAC: cyclo{-[(2S,3R,4R,6E)-3-Hydroxy-4-methyl-2-methylaminooct-6-enoyl]-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-} / CAS. No. 59865-13-3) contained as the active ingredient in RESTASIS ophthalmic solution. Furthermore, cyclosporine or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0041] In the present disclosure, hyaluronic acid refers to the active ingredient in the form of its salt (IUPAC: [→3)-2-Acetamido-2-deoxy-β-D-glucopyranosyl-(1→4)-β-D-glucopyranosyluronic acid-(1→] n / CAS. No. 9067-32-7) is a compound formulated in hyalein eye drops. The weight-average molecular weight of hyaluronic acid, or a pharmaceutically acceptable salt or solvate thereof, is usually 500,000 to 1,200,000, and preferably 600,000 to 1,200,000. As hyaluronic acid, or a pharmaceutically acceptable salt or solvate thereof, commercially available compounds, compounds produced by methods known in the literature, or pharmaceutically acceptable salts or solvates thereof can be used.

[0042] In the present disclosure, loteprednol etabonate is a compound (IUPAC: Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate / CAS. No. 82034-46-6) contained in EYSUVIS ophthalmic solution as an active ingredient. Furthermore, loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0043] In the present disclosure, bromfenac refers to a compound whose salt form is incorporated as the active ingredient in Bronac ophthalmic solution (Sodium 2-[2-amino-3-(4-bromobenzoyl)phenyl acetate sesquihydrate / CAS. No. 120638-55-3). Bromfenac or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0044] In the present disclosure, fluorometholone refers to a compound (IUPAC: 9-Fluoro-11β,17-dihydroxy-6α-methylpregna-1,4-diene-3,20-dione / CAS. No. 426-13-1) contained in flumetholone ophthalmic solution as an active ingredient. Fluorometholone or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0045] In the present disclosure, rebamipide is a compound contained in Mucosta ophthalmic solution as an active ingredient (IUPAC: (2RS)-2-(4-Chlorobenzoylamino)-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid / CAS. No. 90098-04-7). Rebamipide or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0046] In the present disclosure, olodaterol is a compound whose salt form is incorporated as the active ingredient (6-Hydroxy-8-((1R)-1-hydroxy-2-{[1-(4-methoxyphenyl)-2-methylpropane-2-yl]amino}ethyl)-2H-1,4-benzooxazine-3(4H)-one hydrochloride / CAS. No. 869477-96-3) into Spiolto Respimat 28 inhalant. Furthermore, as olodaterol or a pharmaceutically acceptable salt or solvate thereof, a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof can be used.

[0047] In the present disclosure, delcocitinib is a compound known as a Janus kinase (JAK) inhibitor (IUPAC: 3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile / CAS. No. 869477-96-3). Delcocitinib or a pharmaceutically acceptable salt or solvate thereof may be a commercially available compound, a compound produced by a method known in the literature, or a pharmaceutically acceptable salt or solvate thereof.

[0048] The pharmaceutically acceptable salts of the first and second components of the present disclosure are not particularly limited as long as they are each independently pharmaceutically acceptable salts, and specific examples thereof include mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; aliphatic monocarboxylic acids such as formic acid, acetic acid, propionic acid, butyric acid, valeric acid, enanthic acid, capric acid, myristic acid, palmitic acid, stearic acid, lactic acid, sorbic acid, and mandelic acid; aromatic monocarboxylic acids such as benzoic acid and salicylic acid; and aliphatic dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, malic acid, and tartaric acid. Examples of the acid addition salts include organic carboxylic acids such as aliphatic tricarboxylic acids such as benzoic acid and citric acid; organic sulfonic acids such as aliphatic sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, and 2-hydroxyethanesulfonic acid; and aromatic sulfonic acids such as benzenesulfonic acid and p-toluenesulfonic acid; inorganic base addition salts with metals such as alkali metals or alkaline earth metals such as sodium, potassium, magnesium, and calcium; and organic base addition salts with methylamine, ethylamine, ethanolamine, pyridine, lysine, arginine, ornithine, etc.

[0049] These salts can be obtained by a conventional method, for example, by mixing a solution containing an equivalent amount of a compound of the present disclosure and the desired acid or base, and collecting the desired salt by filtration or by distilling off the solvent. In addition, the compound of the present disclosure or a salt thereof can form a solvate with a solvent such as water or ethanol.

[0050] (E)-2-(7-Trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide has excellent Transient Receptor Potential Vanilloid 1 (hereinafter referred to as "TRPV1." TRPV1 is also called "Transient Receptor Potential Vanilloid 1" or "Vanilloid Receptor 1 (VR1)") antagonistic activity.

[0051] The R-form (compound (1)), S-form, or racemic form of ((E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide is described in WO 2007 / 010383, JP 4754566, JP 6230743, WO 2018 / 221543, JP 6830569, WO 2021 / 038889, and WO 2021 / 039023. The R-form (compound (1)), S-form, or racemic form can be produced by the production method described in the publication. The contents of the publication are incorporated herein by reference in their entirety.

[0052] TRPV1 was cloned from the dorsal root ganglion (DRG) as a capsaicin-responsive cation channel. It is also sensitive to heat above 43°C and protons, and is a TRP channel that has been studied as a key molecule in nociception (Biochemistry, Vol. 85, No. 7: 561-565). TRPV1 activity is known to increase during inflammation and tissue injury, inducing hyperalgesia. Therefore, TRPV1 has attracted attention as a potential drug target for pain treatment.

[0053] TRPV1 antagonists have been reported to be effective against various pain models, such as inflammatory pain, neuropathic pain, and osteoarthritis pain (Seikagaku, Vol. 85, No. 7: 561-565).

[0054] In the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, is mixed with at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof to prepare an aqueous suspension, thereby improving the redispersibility of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.

[0055] In another aspect of the present disclosure, there can be provided a composition for improving the redispersibility of an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the composition comprising at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

[0056] In another aspect of the present disclosure, there can be provided a composition for improving the redispersibility of an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the composition comprising at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof, and a nonionic surfactant.

[0057] In another aspect of the present disclosure, there can be provided a composition for improving the redispersibility of an aqueous suspension comprising (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, the composition comprising at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof; a nonionic surfactant; and boric acid.

[0058] In one embodiment of the present disclosure, (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of generally about 0.01 w / v % to about 5 w / v %, preferably about 0.1 w / v % to about 3 w / v %, more preferably about 0.2 w / v % to about 2 w / v %, particularly preferably about 0.2 w / v % to about 1.5 w / v %, and even more preferably about 0.3 w / v % to about 1.0 w / v %.

[0059] In one embodiment of the present disclosure, when the R-isomer of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, is used, it can be present in the aqueous suspension of the present disclosure at a concentration of generally about 0.01 w / v % to about 5 w / v %, preferably about 0.1 w / v % to about 3 w / v %, more preferably about 0.2 w / v % to about 2% w / v %, particularly preferably about 0.2 w / v % to about 1.5 w / v %, and even more preferably about 0.3 w / v % to about 1.0 w / v %.

[0060] In one embodiment of the present disclosure, the nonionic surfactant is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include tyloxapol, polyoxyl stearates (polyethylene glycol monostearate, polyethylene glycol 40 monostearate (MYS-40), polyethylene glycol 400 monostearate, etc.), polyoxyethylene sorbitan fatty acid esters (polyoxyethylene sorbitan monooleate (polysorbate 80), polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan tristearate, etc.), and polyoxyethylene hydrogenated castor oils (polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50, polyoxyethylene hydrogenated castor oil 60 (HCO-60), etc.). These nonionic surfactants may be used alone or in combination of two or more. From the viewpoint of redispersibility or stability of the aqueous suspension, the nonionic surfactant is preferably tyloxapol, polysorbate 80, polyethylene glycol monostearate, or polyoxyethylene hydrogenated castor oil 60, more preferably tyloxapol, polysorbate 80, or polyethylene glycol monostearate, and even more preferably tyloxapol.

[0061] In one embodiment of the present disclosure, the nonionic surfactant can be present in the aqueous suspension of the present disclosure at a concentration of about 0.0001 w / v % to about 1 w / v %, preferably about 0.0005 w / v % to about 0.5 w / v %, more preferably about 0.001 w / v % to about 0.5 w / v %, particularly preferably about 0.005 w / v % to about 0.1 w / v %, and even more preferably about 0.01 w / v % to about 0.05 w / v %.

[0062] In one embodiment of the present disclosure, when tyloxapol is used as the nonionic surfactant, it can be present in the aqueous suspension of the present disclosure at a concentration of about 0.0001 w / v % to about 1 w / v %, preferably about 0.0005 w / v % to about 0.5 w / v %, more preferably about 0.001 w / v % to about 0.5 w / v %, particularly preferably about 0.005 w / v % to about 0.1 w / v %, and even more preferably about 0.01 w / v % to about 0.05 w / v %.

[0063] In one embodiment of the present disclosure, the second component can be present in the aqueous suspension of the present disclosure at a concentration of about 0.005% w / v to about 12% w / v, preferably about 0.005% w / v to about 10% w / v.

[0064] In one embodiment of the present disclosure, diquafosol, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of about 0.3 w / v% to about 12 w / v%, preferably about 0.3 w / v% to about 10 w / v%, and more preferably about 3 w / v% to about 5 w / v%. Without being bound by theory, mixing diquafosol with (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, can improve the redispersibility of the aqueous suspension. Furthermore, unless otherwise specified, the concentration of diquafosol, or a pharmaceutically acceptable salt or solvate thereof, referred to herein is the concentration converted into diquafosol sodium.

[0065] In one embodiment of the present disclosure, cyclosporine, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of about 0.005 w / v % to about 1 w / v %, preferably about 0.005 w / v % to about 0.5 w / v %, and more preferably about 0.05 w / v % to about 0.1 w / v %. Furthermore, the concentration of cyclosporine, or a pharmaceutically acceptable salt or solvate thereof, as used herein, is the concentration converted to cyclosporine (free form), unless otherwise specified.

[0066] In one embodiment of the present disclosure, hyaluronic acid, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of about 0.01% w / v to about 2% w / v, preferably about 0.01% w / v to about 1% w / v, and more preferably about 0.1% w / v to about 0.5% w / v. Furthermore, the concentrations of hyaluronic acid, or a pharmaceutically acceptable salt or solvate thereof, as used herein, are expressed in terms of sodium hyaluronate, unless otherwise specified.

[0067] In one embodiment of the present disclosure, loteprednol etabonate, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of about 0.025% to about 3% w / v, preferably about 0.025% to about 2.5% w / v, and more preferably about 0.25% to about 1% w / v. Furthermore, the concentration of loteprednol etabonate, or a pharmaceutically acceptable salt or solvate thereof, as used herein, is the concentration converted to loteprednol etabonate (free form) unless otherwise specified.

[0068] In one embodiment of the present disclosure, bromfenac or a pharmaceutically acceptable salt or solvate thereof may be present in the aqueous suspension of the present disclosure at a concentration of about 0.01 w / v% to about 2 w / v%, preferably about 0.01 w / v% to about 1 w / v%, and more preferably about 0.1 w / v% to about 0.5 w / v%. Furthermore, the concentration of bromfenac or a pharmaceutically acceptable salt or solvate thereof herein is the concentration converted to bromfenac sodium 1.5 hydrate, unless otherwise specified.

[0069] In one embodiment of the present disclosure, fluorometholone, or a pharmaceutically acceptable salt or solvate thereof, can be present in the aqueous suspension of the present disclosure at a concentration of about 0.01 w / v % to about 2 w / v %, preferably about 0.01 w / v % to about 1 w / v %, and more preferably about 0.1 w / v % to about 0.5 w / v %. Furthermore, the concentration of fluorometholone, or a pharmaceutically acceptable salt or solvate thereof, as used herein, is the concentration converted to fluorometholone (free form), unless otherwise specified.

[0070] In one embodiment of the present disclosure, the aqueous suspension of the present disclosure can contain any additional active ingredient in addition to the first and second components.

[0071] (Redispersibility) (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, has low solubility in water. Therefore, in the absence of a dispersant such as a nonionic surfactant, an ionic surfactant, or a water-soluble polymer, the particles float on the water surface, making it impossible to prepare an aqueous suspension. In addition, when a dispersant other than a nonionic surfactant is used, the dispersant must be incorporated at a concentration substantially exceeding the pharmaceutically acceptable concentration, making it essential to incorporate a nonionic surfactant into the aqueous suspension. According to the present disclosure, an aqueous suspension with improved redispersibility can be provided by incorporating any amount of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, or a pharmaceutically acceptable salt or solvate thereof in the presence of a nonionic surfactant as a dispersant.

[0072] In one embodiment of the present disclosure, an aqueous suspension having improved redispersibility can be provided by blending (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof, with at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

[0073] Measurements using the falling operation can be said to reproduce the evaluation when used by patients whose hands have weakened due to some kind of disability or symptom, making it difficult to redisperse the tablet by shaking, and therefore can also be said to evaluate the redispersibility when used by these patients and elderly people.

[0074] In one embodiment, the redispersibility can be determined to be improved when the number of inversion operations required for the redispersion described above is typically about 44 times or less, preferably about 40 times or less, more preferably about 35 times or less, particularly preferably about 30 times or less, even more preferably about 25 times or less, and most preferably about 20 times or less.

[0075] In one embodiment, the redispersibility can be evaluated by any means, for example, by filling a container with the aqueous suspension of the present disclosure and measuring the number of times the container is shaken at any speed and / or any amplitude, or inverted, until the suspended particles are redispersed.

[0076] In one embodiment, the average particle size (D) of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in an aqueous suspension of the present disclosure is 50Although the average particle size is not particularly limited, it can be generally about 0.1 μm to about 50 μm, preferably about 0.5 μm to about 10 μm, particularly preferably about 1 μm to about 10 μm, and even more preferably about 1 μm to about 5 μm. By setting the average particle size in this range, redispersibility can be improved.

[0077] In one embodiment, the (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension of the present disclosure can be used in a crystalline form, and the crystalline form is not particularly limited as long as it does not affect redispersibility. For example, in the present disclosure, Type I crystals, Type II crystals, Type III crystals, or mixtures thereof of (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide disclosed in WO 2018 / 221543, Japanese Patent No. 6230743, etc. can be used. Preferably, Type I crystals are used.

[0078] In one embodiment of the present disclosure, the aqueous suspension is an ophthalmic suspension, and may be provided as an ophthalmic injection, eye drop, or ophthalmic irrigation solution. For example, the ophthalmic suspension may be provided in the form of a suspension in which the active ingredient is suspended in an aqueous solvent (e.g., phosphate buffered saline), or in the form of a solution in which the active ingredient is dissolved.

[0079] In one embodiment of the present disclosure, the aqueous suspension may be an eye drop for treating dry eye. Dry eye is a disease accompanied by subjective symptoms such as ocular discomfort, and requires long-term and regular treatment. In addition, since dry eye treatments are generally administered frequently, there is a strong demand for formulations that are easy to use and that facilitate patient adherence. Furthermore, in the case of a suspension with poor redispersibility, there is a concern that the suspended particles may not be uniformly dispersed, the desired active ingredient may not be administered, and the pharmacological effect may not be fully exerted. From these perspectives, redispersibility is a major issue in eye drops for treating dry eye, and the provision of an aqueous suspension with excellent redispersibility according to the present disclosure is of great value.

[0080] The aqueous suspensions of the present disclosure may be administered by any suitable route as determined by one of skill in the art, and may be formulated to be suitable for administration by a route selected from, but not limited to, ocular injection, topical application (including application to the eye), eye drops, intravenous injection, infusion, oral, parenteral, transdermal, and the like.

[0081] Additives and / or Excipients Aqueous suspensions of the present disclosure may contain any pharmaceutically acceptable additives and / or excipients known in the art, including, but not limited to, viscosity agents, stabilizers, pH adjusting agents, buffers, and preservatives.

[0082] The thickener is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include water-soluble polymers such as carboxyvinyl polymer, polyvinylpyrrolidone, polyethylene glycol, polyvinyl alcohol, xanthan gum, sodium chondroitin sulfate, sodium hyaluronate, etc.; cellulose-based polymers such as hydroxyethyl cellulose, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl cellulose, etc. These thickeners may be used alone or in combination of two or more.From the viewpoint of redispersibility, cellulose-based polymers are preferred, and methyl cellulose is particularly preferred.

[0083] The stabilizer is not particularly limited as long as it is pharmaceutically acceptable, but examples thereof include polyvinylpyrrolidone, monoethanolamine, cyclodextrin, dextran, ascorbic acid, tocopherol, dibutylhydroxytoluene, sulfites, etc., and the content thereof is preferably about 0.001 w / v % to about 1 w / v % of the total amount of the composition.

[0084] The pH adjuster is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include acids such as hydrochloric acid, acetic acid, boric acid, aminoethylsulfonic acid, and epsilon-aminocaproic acid; alkalis such as sodium hydroxide, potassium hydroxide, borax, triethanolamine, monoethanolamine, sodium bicarbonate, and sodium carbonate; and the content thereof is, for example, 0 to about 20 w / v % based on the total amount of the aqueous suspension.

[0085] In one embodiment of the present disclosure, the aqueous suspension of the present disclosure can be mixed with the above-mentioned pH adjuster as needed to adjust the pH to generally about 4 to about 8, preferably about 5.0 to about 8.0, more preferably about 6.0 to about 8.0, particularly preferably about 7.0 to about 8.0, and even more preferably about 7.2 to about 7.8.

[0086] The buffer used in the aqueous suspension of the present disclosure is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include borate buffer, phosphate buffer, Tris buffer, citrate buffer, tartrate buffer, acetate buffer, amino acid buffer, etc., but from the viewpoint of redispersibility or stability of the aqueous suspension, borate buffer or phosphate buffer is preferred, and borate buffer is particularly preferred.

[0087] The concentration of the buffering agent may be appropriately set within a range that can impart the desired buffering ability to the aqueous liquid preparation, and may be, for example, about 0.1 w / v % to about 10 w / v %, and from the viewpoint of improving redispersibility or stability, preferably about 1 w / v % to about 5 w / v %, more preferably about 1 w / v % to about 3 w / v %.

[0088] The boric acid buffer is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include boric acid and / or its salts. The boric acid is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include orthoboric acid, metaboric acid, tetraboric acid, etc. The salt of boric acid is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include metal salts such as sodium salt, potassium salt, calcium salt, magnesium salt, and aluminum salt; and organic amine salts such as triethylamine, triethanolamine, morpholine, piperazine, and pyrrolidine. Boric acid or its salts may be used alone or in combination of two or more. Furthermore, a preferred embodiment of the boric acid buffer is a combination of boric acid and borax.

[0089] When boric acid and borax are used in combination, the ratio of boric acid to borax is not particularly limited, but may be, for example, 10 to 300 parts by mass, preferably 10 to 250 parts by mass, more preferably 30 to 100 parts by mass, and particularly preferably 40 to 60 parts by mass of borax per 100 parts by mass of boric acid.

[0090] Specific examples of phosphate buffers include phosphoric acid and / or its salts. Phosphate salts are not particularly limited as long as they are pharmaceutically acceptable, and include, for example, dialkali metal hydrogen phosphates such as disodium hydrogen phosphate and dipotassium hydrogen phosphate; alkali metal dihydrogen phosphates such as sodium dihydrogen phosphate and potassium dihydrogen phosphate; and trialkali metal phosphates such as trisodium phosphate and tripotassium phosphate. Phosphate salts may also be in the form of solvates such as hydrates, for example, disodium hydrogen phosphate may be in the form of a dodecahydrate, and sodium dihydrogen phosphate may be in the form of a dihydrate. Phosphate buffers may be selected from phosphoric acid and its salts and used alone or in combination of two or more. Among phosphoric acid and its salts, preferred are phosphates, more preferably at least one of dialkali metal hydrogen phosphates and alkali metal dihydrogen phosphates, and particularly preferably at least one of disodium hydrogen phosphate and sodium dihydrogen phosphate.

[0091] Examples of Tris buffers include Tris (also known as trishydroxymethylaminomethane) and / or its salts. The Tris salts are not particularly limited as long as they are pharmaceutically acceptable, and examples include acetate, hydrochloride, maleate, sulfonate, and the like. As the Tris acid buffer, one selected from Tris and its salts may be used alone, or two or more may be used in combination. In another embodiment, specific examples of Tris buffers include trometamol and / or its salts. As the salt of trometamol, there are no particular limitations, as long as it is pharmaceutically acceptable, and examples include organic acid salts such as acetate; and inorganic acid salts such as hydrochloride and sulfonate. As the Tris acid buffer, one selected from trometamol and its salts may be used alone, or two or more may be used in combination. Among trometamol and its salts, trometamol is preferred.

[0092] Specific examples of citrate buffers include citric acid and / or its salts. The citric acid salts are not particularly limited as long as they are pharmaceutically acceptable, and include, for example, alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt. The citric acid salt may also be in the form of a solvate such as a hydrate. As the citrate buffer, one selected from citric acid and its salts may be used alone, or two or more may be used in combination. Among citric acid and its salts, preferred are citric acid salts, more preferred are alkali metal citric acid salts, and particularly preferred is sodium citrate.

[0093] Specific examples of tartaric acid buffers include tartaric acid and / or its salts. The salts of tartaric acid are not particularly limited as long as they are pharmaceutically acceptable, and include, for example, alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts. The salts of tartaric acid may also be in the form of solvates such as hydrates. As the tartaric acid buffer, one selected from tartaric acid and its salts may be used alone, or two or more may be used in combination.

[0094] Specific examples of acetate buffers include acetic acid and / or its salts. The salts of acetic acid are not particularly limited as long as they are pharmaceutically acceptable, and examples include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; and ammonium salts. Furthermore, the salts of acetic acid may be in the form of a solvate such as a hydrate. Acetic acid and its salts may be used singly or in combination as the acetate buffer.

[0095] Specific examples of the amino acid buffer include acidic amino acids and / or their salts. Specific examples of the acidic amino acids include aspartic acid and glutamic acid. The salts of acidic amino acids are not particularly limited as long as they are pharmaceutically acceptable, and examples include alkali metal salts such as sodium salts and potassium salts. As the amino acid buffer, one kind selected from acidic amino acids and their salts may be used alone, or two or more kinds may be used in combination.

[0096] The preservative is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include sorbic acid, potassium sorbate, parahydroxybenzoic acid esters such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, and butyl parahydroxybenzoate, chlorhexidine gluconate, quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, and cetylpyridinium chloride, alkylpolyaminoethylglycine, chlorobutanol, polyquad, polyhexamethylene biguanide, and chlorhexidine. The content thereof can be appropriately varied depending on the type, and can be, for example, about 0.0001 w / v % to about 0.2 w / v % based on the total amount of the aqueous suspension.

[0097] When preparing eye drops, for example, the desired components described above can be dissolved or suspended in an aqueous solvent such as sterilized purified water, physiological saline, or a buffer solution (e.g., phosphate buffer, citrate buffer, or acetate buffer), or in a non-aqueous solvent such as a vegetable oil such as cottonseed oil, soybean oil, sesame oil, or peanut oil, and the like, and the resulting solution is adjusted to a predetermined osmotic pressure and subjected to a sterilization treatment such as filtration sterilization.

[0098] (Container) The container for housing the aqueous suspension of the present disclosure is not particularly limited, and examples thereof include glass containers and plastic containers. Plastic containers can be made of any material, such as polyester (polyethylene terephthalate, polyarylate), polycarbonate, polyethylene, polypropylene, mixtures thereof, or mixtures of these with other materials. Containers used in the present disclosure may be those used in the medical field or other fields. In one embodiment, the container can be made of any material that meets the "Standards for Plastic Containers for Ophthalmic Solutions" in Japan or other equivalent standards.

[0099] The shape of the container to be used may be any shape, and generally any shape suitable for eye drops can be used.

[0100] In certain embodiments, the aqueous suspension of the present disclosure can be filled into any eye drop container commonly used in the medical field, for example, a polyethylene (preferably low-density polyethylene) or polypropylene, preferably a colorless polypropylene container.

[0101] (General Techniques) The molecular biological, biochemical and microbiological techniques used herein are well known and commonly used in the art, and are described in, for example, Sambrook J. et al. (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor and its 3rd Ed. (2001); Ausubel, F. M. (1987). Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Ausubel, F. M. (1989). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Innis, M. A. (1990). PCR Protocols: A Guide to Methods and Applications, Academic Press; Ausubel, F. M. (1992). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Ausubel, FM (1995). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Innis, MA et al. (1995). PCR Strategies, Academic Press; Ausubel, FM (1999).Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, and annual updates; Sninsky, JJet al.(1999).PCR Applications: Protocols for Functional Genomics, Academic Press, Gait, MJ(1985).Oligonucleotide Synthesis: A Practical Approach, IRL Press; Gait, MJ(1990).Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein, F. (1991).Oligonucleotides and Analogues: A Practical Approach, IRL Press; Adams, RL et al.(1992).The Biochemistry of the Nucleic Acids, Chapman & Hall; Shabarova, Z. et al.(1994).Advanced Organic Chemistry of Nucleic Acids, Weinheim; Blackburn, GM et al.(1996).Nucleic Acids in Chemistry and Biology, Oxford University Press; Hermanson, GT (1996). Bioconjugate Techniques, Academic Press; Special Edition of Experimental Medicine "Gene Transfer & Expression Analysis Experimental Methods," Yodosha, 1997. These are incorporated herein by reference in their entirety (perhaps in their entirety).

[0102] All references cited herein, including scientific literature, patents, patent applications, and the like, are incorporated by reference in their entirety to the same extent as if each were specifically set forth.

[0103] The present disclosure has been described above by showing preferred embodiments for ease of understanding. Hereinafter, the present disclosure will be described based on examples. However, the above description and the following examples are provided for illustrative purposes only and are not intended to limit the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described herein, but is limited only by the scope of the claims.

[0104] Test Example 1: Evaluation of redispersibility Preparation of suspensions A base solution was prepared according to the composition shown in Tables 1 to 6, and compound (1) was added thereto and dispersed by stirring to obtain a suspension. Tyloxapol manufactured by AMRI Rensselaer (Curia Global, Inc.), polysorbate 80 manufactured by NOF Corp., polyethylene glycol monostearate 40 (MYS-40) manufactured by Nippon Surfactant Industry Co., Ltd., and polyoxyethylene hydrogenated castor oil 60 manufactured by Nippon Surfactant Industry Co., Ltd. were used. The above-mentioned type I crystals were used as compound (1). Diquafosol sodium was manufactured by Kyongbo Co., Ltd., cyclosporine was manufactured by Tokyo Chemical Industry Co., Ltd., sodium hyaluronate was manufactured by Seikagaku Corporation, loteprednol etabonate was manufactured by Jinan Chenghui Shuangda Chemical Co., Ltd., bromfenac sodium was manufactured by Regis Co., Ltd., and fluorometholone was manufactured by Cicol Co., Ltd.

[0105] The prepared suspension was stirred with a stirrer and 5 mL of each was dispensed into an eye dropper container. The eye dropper container used was a colorless polyethylene container (the same container used for GatiFlo ophthalmic solution 0.3% (manufactured and sold by Senju Pharmaceutical Co., Ltd.)).

[0106] Evaluation of redispersibility (inversion) Complete settling of suspended particles in the suspension filled in the eye drop container was confirmed. Inversion (the action of holding the container in the hand and turning it upside down) was performed and repeated until the precipitate disappeared from the bottom and walls of the eye drop container and redispersion occurred. The number of inversions required for redispersion was counted. One inversion was defined as an operation of inverting the container 180° upside down at a rate of 1 second, then inverting it 180° again to the upright position. The test was performed on 3 to 6 samples per formulation, and the average number of inversions was calculated.

[0107] Results The results are shown in Tables 1 to 7. The aqueous suspension containing compound (1) reduced the number of inversion operations and showed good redispersibility by incorporating diquafosol sodium, cyclosporine, sodium hyaluronate, loteprednol etabonate, bromfenac sodium, or fluorometholone. When Example 1 was evaluated by shaking, the number of shaking operations was 10.0.

[0108]

[0109]

[0110]

[0111]

[0112]

[0113]

[0114]

[0115] (Preparation Examples) Eye drops can be prepared by preparing aqueous suspensions having the compositions shown in Tables 8 and 9. The amounts of compound (1) and each additive are expressed as "g / 100 mL."

[0116]

[0117]

[0118] Tyloxapol (cloud point: 90-100°C) manufactured by AMRI Rensselaer (Curia Global, Inc.) is used, methylcellulose is Metrose SM-15 manufactured by Shin-Etsu Chemical Co., Ltd., hydroxypropyl methylcellulose (HPMC) is 60SH-4000 manufactured by Shin-Etsu Chemical Co., Ltd., carboxymethylcellulose (CMC) is Cellogen PR-S manufactured by Dai-ichi Kogyo Seiyaku Co., Ltd., and lifitegrast is manufactured by Shanghai Sumway Pharmaceutical Technology Co., Ltd. Type I crystals of compound (1) are used.

[0119] Specifications of each container Each container consists of a bottle (colorless PE, colorless PP, or brown PP), a nozzle (PE), and a cap (PP). The appearance, lightness, chromaticity, saturation, and transmittance at each wavelength of the bottle body of each container are as shown in Table 10 and Figure 1. Each container is shrink-wrapped with a product label.

[0120]

[0121] The bottle dimensions are approximately 23 mm x 17 mm x 50 mm, and the resin weight is approximately 3 g. The shape is similar to that of the bottle of Softear (registered trademark) 0.02% eye drops (manufactured and sold by Senju Pharmaceutical Co., Ltd.).

[0122] The polyethylene bottle is made of low-density polyethylene. The polypropylene is a propylene-ethylene copolymer with a propylene / ethylene ratio of 50 / 50 to 99.9 / 0.1, similar to the material used in the bottle of Softear (registered trademark) 0.02% eye drops (manufactured and sold by Senju Pharmaceutical Co., Ltd.).

[0123] Measurement method for lightness, saturation, and transmittance of bottle body The side portion (wider side portion, 1.0 cm x 2.0-3.0 cm) cut from the bottle body was measured for lightness (L * value) and chromaticity (a * value, b * value) is measured. * value) 2 +(b * value) 2 ) 1/2 According to * Furthermore, the transmittance (%) of light in the range of 200 to 800 nm was measured for this side surface using an ultraviolet-visible spectrophotometer ("UV-2450 model", manufactured by Shimadzu Corporation).

[0124] Bottle sterilization methods EB (electron beam sterilization): Eye drop bottles are sterilized by irradiating them with electron beams at 10-60 kGy. EOG (ethylene oxide gas sterilization): Eye drop bottles are sterilized under the following conditions: ethylene oxide concentration 400-700 mg / L, temperature 40-50°C, relative humidity 45-85%, and treatment time 3 hours or more. VHP (vaporous hydrogen peroxide): Eye drop bottles are sterilized by spraying them with 3% VHP, temperature 20-50°C, relative humidity 30-90%, and treatment time approximately 1 hour. Gamma rays (gamma ray sterilization): Bottles are sterilized by irradiating them with gamma rays at 20-60 kGy.

[0125] 50L-scale manufacturing method for eye drops: Purified water and the specified amounts of boric acid, borax, sodium chloride, and zinc chloride are added to a 30L stainless steel container and stirred. A specified amount of tyloxapol aqueous solution is prepared in a 1L stainless steel container, and this aqueous solution is added to the 30L stainless steel container. A specified amount of methylcellulose is dispersed in hot water (50-90°C) in a separate 1L stainless steel container, then cooled, and this methylcellulose aqueous solution is added to the 30L stainless steel container. After confirming that all additives have dissolved in the 30L stainless steel container, purified water is added to make a 1.5x concentrated base solution, and the weight is made up to the desired level. This base solution is sterilized by filtration, and the weight is made up to the desired level with purified water (including rinse-in). The first component, compound (1), and the second component (dicafossol sodium, cyclosporine, sodium hyaluronate, loteprednol etabonate, bromfenac sodium, fluorometholone, rebamipide, olodaterol hydrochloride, or delcocitinib) are added to this base solution and dispersed by stirring to prepare a suspension. After confirming that compound (1) is dispersed in the liquid, the suspension is gently stirred to defoam. The suspension is then roughly filtered using a filter with a pore size of 75 μm, and the suspension is filled into a bottle while stirring, and then a nozzle and a cap are attached to the bottle.

[0126] (Note) As described above, the present disclosure has been illustrated using preferred embodiments thereof, but it is understood that the scope of the present disclosure should be interpreted solely by the scope of the claims. It is understood that the patents, patent applications, and other documents cited in this specification are incorporated by reference into this specification in their entirety as if the contents themselves were specifically set forth herein. This application claims priority to Japanese Patent Application No. 2022-156062 filed with the Japan Patent Office, the contents of which are incorporated herein in their entirety.

[0127] The present disclosure is applicable to fields such as medicine, pharmaceuticals, healthcare, biology, and biochemistry.

Claims

1. An aqueous suspension comprising a first component and a second component, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide or a pharmaceutically acceptable salt or solvate thereof, and the second component is at least one selected from the group consisting of diquafosol, cyclosporine, hyaluronic acid, loteprednol etabonate, bromfenac, fluorometholone, and a pharmaceutically acceptable salt or solvate thereof.

2. The aqueous suspension of claim 1, further comprising a nonionic surfactant.

3. The aqueous suspension of claim 2, wherein the nonionic surfactant is at least one selected from the group consisting of tyloxapol, polysorbate 80, polyethylene glycol 40 monostearate, and polyoxyethylene hydrogenated castor oil 60.

4. The aqueous suspension of claim 2, wherein the nonionic surfactant is tyloxapol.

5. The aqueous suspension of claim 2, wherein the concentration of said nonionic surfactant in said aqueous suspension is from about 0.0001% w / v to about 1% w / v.

6. The aqueous suspension according to claim 1, wherein the concentration of said first component in said aqueous suspension is from about 0.01 w / v % to about 5 w / v %.

7. The concentration of the diquafosol or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.3 w / v% to about 10 w / v%, the concentration of the cyclosporine or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.005 w / v% to about 0.5 w / v%, the concentration of the hyaluronic acid or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v% to about 1 w / v%, the concentration of the loteprednol etabonate or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.025 w / v% to about 2.5 w / v%, and the concentration of the bromfenac or a pharmaceutically acceptable salt or solvate thereof in the aqueous suspension is about 0.01 w / v% to about 1 w / v%, 2. The aqueous suspension of claim 1, wherein the concentration of fluorometholone, or a pharmaceutically acceptable salt or solvate thereof, in the aqueous suspension is from about 0.01% w / v to about 1% w / v.

8. The aqueous suspension of any one of claims 1 to 7, wherein the first component is (E)-2-(7-trifluoromethylchroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide, or a pharmaceutically acceptable salt or solvate thereof.